“Nothing is over yet”: Russian scientists on COVID-19

The danger continues

This year’s agenda focuses on current issues aimed at ensuring the sanitary and epidemiological well-being of the Russian Federation, mainly the consequences of the two-year pandemic.

“Nothing is finished, the situation today is localized and cannot be considered complete. And every time the measures for this infection are weakened in an important place, we see more growth, ”said Anna Popova, the chief medical doctor of the Russian Federation, head of Rospotrebnadzor, at the congress assessing the current situation with COVID-19 in Russia.

COVID-19 gradually takes on the signs of seasonal ARVI, but retains all the signs of a particularly dangerous infection, especially for patients at risk. The danger lurks in the similarity of the symptoms of COVID-19, flu, and seasonal SARS. Scientists around the world are looking for universal antiviral drugs by studying already known molecules containing umifenovir.

Modern approach to treatment

Symposium “Clinical and epidemiological consequences of influenza and COVID-19 in the 2021-2022 season. At the meeting titled “Forecasts for the Future” chaired by Vladimir Chulanov, Chief Freelance Specialist of Infectious Diseases of the Russian Ministry of Health and Academician Viktor Maleev, he gave a summary of the latest research on coronavirus infection in Russia and the world. The topics of the reports are “Features of the virology and epidemiology of the influenza virus in the current season” (EI Burtseva), “Antiviral activity against coronaviruses: Preclinical studies in Russia” (IA Leneva), “Evidence comes from practice. Results of a pharmacoepidemiological study in COVID-19” (N.Yu. Pshenichnaya).

According to the speaker of the symposium, Doctor of Biological Sciences, Head of Experimental Virology Laboratory of Virology Department. OG Andzhaparidze Federal State Budgetary Scientific Institution “NIIVS them. II Mechnikov” Irina Leneva, speaking about umifenovir as a universal antiviral drug, “when taken, viruses are blocked from entering the cell.”

“It acts directly on various respiratory viruses without affecting the human immune system. This mechanism of action on specific viral proteins is well understood. If we are talking about different strains of COVID-19, including “Omicron”, it is because of the blockade of hedgehog. In the case of influenza, it is hemagglutinin. The drug It is among the recommendations of the Ministry of Health for the treatment and prevention of COVID-19.

“The key principle,” Leneva concluded, “is to start taking broad-spectrum antiviral drugs early in the outpatient phase of treatment, which helps reduce the risk of complications.”

The symptoms of all acute respiratory viral infections (ARVI), including influenza and COVID-19, are very similar. We need time to correctly diagnose the cause of the disease, which is out of our hands, because the sooner adequate treatment is started, the more effective it is,” said Elena Burtseva, another participant of the symposium.

According to him, timely initiation of therapy reduces the risk of complications, and at the first symptoms of SARS, direct-acting antiviral drugs such as umifenovir (for example, Arbidol) should be started immediately. It is important not to stop taking an antiviral (similar to an antibiotic) and to follow the application process to prevent the viruses from reactivating and continuing to reproduce actively. It is the course reception that can save you from complications.

Leading Russian infectious disease specialists, epidemiologists and virologists met on March 29 at the XIV. After academician VI Pokrovsky “Infectious diseases in the modern world: evolution, current and future threats.

Source: Gazeta


Please enter your comment!
Please enter your name here


More from author